Molecular adsorbent recirculating system and hemostasis in patients at high risk of bleeding: an observational study
Critical Care2006Vol. 10(1), pp. R24–R24
Citations Over TimeTop 10% of 2006 papers
Peter Faybik, Andreas Bacher, Sibylle A Kozek-Langenecker, H. Steltzer, Claus G. Krenn, Sandra Unger, Hubert Hetz
Abstract
MARS treatment appears to be well tolerated during marked coagulopathy due to liver failure. Although MARS leads to a further decrease in platelet count and fibrinogen concentration, platelet function, measured as the contribution of the platelets to the clot firmness in TEG, remains stable. According to TEG-based results, MARS does not enhance fibrinolysis.
Related Papers
- → Mouse models of hemostasis(2020)55 cited
- → Hemostasis and Platelet Dysfunction in Asphyxiated Neonates(2011)51 cited
- Assessment of safety and efficacy of homemade vascular hemostasis device(2009)
- Hemostasis Effect of Disposable Packing Hemostasis on Miniature Pigs(2010)
- → Hemostasis Devices(2007)